COMMUNIQUÉS West-GlobeNewswire

Novartis announces expiration of Regulus Therapeutics tender offer
25/06/2025
Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser [...]
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides
25/06/2025
Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention [...]
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
25/06/2025
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active [...]
Addex Shareholders Approve All Resolutions at Annual General Meeting
25/06/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug [...]
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
25/06/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025 Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible [...]
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
25/06/2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
25/06/2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le [...]
OSE Immunotherapeutics provides an update on ongoing proceedings
25/06/2025
OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25 th , 2025, 8:00 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, [...]
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
25/06/2025
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing [...]
Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
25/06/2025
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of [...]
Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
25/06/2025
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
25/06/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that it is getting closer [...]
Cidara Announces Pricing of Upsized Public Offering of Common Stock
25/06/2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today [...]
Une première autorisation de distribution de la fleur de cannabis médicinal à des fins thérapeutiques délivrée par le ministère de la Santé italien pour Tilray Medical
25/06/2025
SAVONE, Italie, 25 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, ci-après « Tilray », une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique permettant aux [...]
Shiny Smile Veneers Named Top Snap-On Veneer Brand in the US by Independent Review Platforms
24/06/2025
Houston, TX, June 24, 2025 (GLOBE NEWSWIRE) -- Shiny Smile Veneers, a US-based provider of custom-made snap-on veneers, has once again been recognized as one of the top snap-on veneer brands in the country, this time by [...]
Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific Sessions
24/06/2025
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next-generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced [...]
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
24/06/2025
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar [...]
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
24/06/2025
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will [...]
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
24/06/2025
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug [...]

Pages